Proportion of women <30 years of age with high-grade cervical dysplasia and cervical cancer in the south of Brazil

2018 ◽  
Vol 149 ◽  
pp. 240-241
Author(s):  
D. Gottlieb ◽  
S. Pessini ◽  
K.M. Schmeler ◽  
M.P. Salcedo
Keyword(s):  
Cervical Cancer ◽  
Cervical Dysplasia ◽  
High Grade ◽  
The South ◽  
South Of Brazil

scholarly journals High-Grade Cervical Dysplasia following Radiation Therapy for Invasive Cervical Cancer: A Report of Four Cases

2015 ◽  
Vol 8 (2) ◽  
pp. 217-221 ◽  
Author(s):  
Mila Pontremoli Salcedo ◽  
Andrea M. Milbourne ◽  
Anuja Jhingran ◽  
Patricia J. Eifel ◽  
Pedro T. Ramirez ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Radiation Therapy ◽  
Gynecologic Oncology ◽  
Invasive Cervical Cancer ◽  
Locally Advanced ◽  
Cervical Dysplasia ◽  
High Grade ◽  
Advanced Cervical Cancer ◽  
Recurrent Cervical Cancer ◽  
Locally Advanced Cervical Cancer

Introduction: The standard treatment for locally advanced cervical cancer is chemoradiation, with the majority of patients having a complete response to the therapy. The current surveillance recommendations from the Society of Gynecologic Oncology include annual cytology, with a small proportion of patients subsequently diagnosed with high-grade cervical dysplasia (CIN 2/3). To date, there is limited information regarding the optimal treatment and outcome for patients diagnosed with CIN 2/3. The current report describes the diagnosis, management and outcome of 4 patients diagnosed with CIN 2/3 following chemoradiation. Case Description: We describe 4 patients who developed CIN 2/3 seven months to 8 years following radiation therapy for locally advanced cervical cancer. All 4 patients were asymptomatic and the abnormalities were first detected by a Pap test. Three of the patients were managed conservatively with observation, and the CIN 2/3 resolved without intervention. One patient underwent 2 cervical conizations followed by a hysterectomy with no residual dysplasia noted on the hysterectomy specimen. Conclusion: The majority of patients with recurrent cervical cancer after chemoradiation are symptomatic, and most cases are detected by a physical examination. The role of cytology, colposcopy and biopsies may be of limited value. Furthermore, the significance of the diagnosis of CIN 2/3 in patients previously treated with radiation therapy was not associated with recurrent disease in the 4 patients described. Our results suggest that cytology may be of limited value in detecting recurrence in patients following radiation therapy, even when CIN 2/3 is detected.

scholarly journals Safety and Efficacy of the New CryoPop® Cryotherapy Device for Cervical Dysplasia in Low- and Middle-income Countries: Study Protocol for a Multicentre Open-label Non-inferiority Clinical Trial With Historical Controls

2021 ◽  
Author(s):  
S YogeshKumar ◽  
Jean Anderson ◽  
Enrique Lu ◽  
Edward Kenyi ◽  
Margaret Mensa ◽  
...  
Keyword(s):  
Health Care ◽  
Clinical Trial ◽  
Cervical Cancer ◽  
Precancerous Lesions ◽  
Cervical Dysplasia ◽  
High Grade ◽  
Care Providers ◽  
Middle Income ◽  
Middle Income Countries ◽  
Low And Middle Income

Abstract Background: Cervical cancer is the fourth most common cancer in the world, affecting mainly women residing in low- and middle-income countries. Progression from a pre-invasive phase to that of an invasive phase generally takes years and provides a window of opportunity to screen for and treat precancerous lesions. Methods: This study is being conducted at four sites in north Karnataka, India. Community sensitization activities have been organized in the study areas to create awareness among stakeholders, including elected representatives, physicians, health care workers and potential participants. Organized community based as well as hospital-based screening is being conducted using Visual Inspection with Acetic acid (VIA). Screen positive women are referred to respective study hospitals for colposcopy and directed biopsy. Participants with confirmed high-grade cervical dysplasia (high grade squamous intraepithelial lesions or HSIL) who fit all other eligibility criteria will be recruited to the study and will receive cryotherapy using CryoPop®, an innovative new cryotherapy device.Discussion: There is a need to develop an inexpensive, simple and effective cryotherapy device for use by frontline health care providers at locations where screening and timely treatment can be given, accelerating access to cervical cancer prevention services and minimizing loss to follow-up of women with precancerous lesions who need treatment.Trial Registration: Clinical Trial Registry - India CTRI/2019/01/017289 ClinicalTrials.Gov number NCT04154644 on November 6, 2019. https://bit.ly/3yRQWC4

Human Papillomavirus, Smoking, and Cancer

2001 ◽  
Vol 5 (4) ◽  
pp. 323-328 ◽  
Author(s):  
Todd O. Moore ◽  
Angela Yen Moore ◽  
Daniel Carrasco ◽  
Melody Vander Straten ◽  
Istvan Arany ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cancer Progression ◽  
Cervical Dysplasia ◽  
High Grade ◽  
Multivariate Adjustment ◽  
Local Immunosuppression ◽  
Dose Dependent Fashion ◽  
Carcinogenic Effects ◽  
Dose Dependent

Background: The effect of smoking on human papillomavirus (HPV) activity and subsequent dysplasia and neoplasia remains controversial Objective: To determine any reported effects of smoking on either HPV activity or HPV-related dysplasia/cancer using retrospective analysis of the literature from 1966 through 1998 via Toxline and PubMed to search for “smoking,” “papillomavirus,” and “cancer.” Conclusion: Several recent large studies demonstrated that smoking was associated with a greater incidence of cervical, vulvar, penile, anal, oral, and head and neck cancer in a dose-dependent fashion, while other studies did not show any correlation between smoking and cervical dysplasia after multivariate adjustment. Recent studies have also indicated that smoking may be more closely related to high-grade lesions of the cervix and vulva. These data provide evidence of an association between HPV, smoking, and cancer. Progression of dysplasia likewise seems to be associated with smoking. Several groups have attempted to discern whether the connection between smoking and cervical cancer is from local immunosuppression and/or from direct carcinogenic effects.

Abnormal Pap Smear

2020 ◽  
Author(s):  
Huma Farid
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Pap Smear ◽  
Cervical Dysplasia ◽  
The United States ◽  
Pap Smears ◽  
Low Grade ◽  
High Grade ◽  
Increased Risk ◽  
Risk Of Progression

Since the Papanicolaou (Pap) smear became implemented as a screening tool for cervical cancer, the mortality from cervical cancer has sharply declined in the United States. The discovery of the human papillomavirus (HPV) as the causative agent in the progression from dysplasia of the cervix to cervical cancer has changed the types of screening offered to women and the management of abnormal Pap smears. The management of abnormal Pap smears has changed depending on the age of the woman, with women under the age of 24 years being managed more conservatively given the low rates of cervical cancer in this age group and the high rates of regression of HPV and cytologic abnormalities. Colposcopy remains the first line in evaluation of an abnormal Pap smear, with excisional treatment reserved for high-grade dysplasias with a high risk of progression to cervical cancer. Treatment for cervical dysplasia is highly effective, but even after treatment, there is an increased risk of recurrence or progression to cervical cancer for up to 25 years, and these women should be followed closely.  This review contains 18 figures, 3 tables, and 43 references. Key words: cervical cancer screening, high-grade cervical dysplasia, human papillomavirus, low-grade cervical dysplasia, management of abnormal Pap smears, Pap smear, recurrence of cervical dysplasia, treatment of dysplasia

scholarly journals Safety and efficacy of the new CryoPop® cryotherapy device for cervical dysplasia in low- and middle-income countries: study protocol for a multicenter open-label non-inferiority clinical trial with historical controls

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
S. Yogeshkumar ◽  
Jean Anderson ◽  
Enriquito Lu ◽  
Edward Kenyi ◽  
Margaret Mensa ◽  
...  
Keyword(s):  
Health Care ◽  
Clinical Trial ◽  
Cervical Cancer ◽  
Precancerous Lesions ◽  
Cervical Dysplasia ◽  
High Grade ◽  
Care Providers ◽  
Middle Income ◽  
Middle Income Countries ◽  
Low And Middle Income

Abstract Background Cervical cancer is the fourth most common cancer in the world, affecting mainly women residing in low- and middle-income countries. Progression from a pre-invasive phase to that of an invasive phase generally takes years and provides a window of opportunity to screen for and treat precancerous lesions. Methods This study is being conducted at four sites in north Karnataka, India. Community sensitization activities have been organized in the study areas to create awareness among stakeholders, including elected representatives, physicians, health care workers, and potential participants. Organized community based as well as hospital-based screening is being conducted using visual inspection with acetic acid (VIA). Screen positive women are referred to respective study hospitals for colposcopy and directed biopsy. Participants with confirmed high-grade cervical dysplasia (high-grade squamous intraepithelial lesions or HSIL) who fit all other eligibility criteria will be recruited to the study and will receive cryotherapy using CryoPop®, an innovative new cryotherapy device. Discussion There is a need to develop an inexpensive, simple, and effective cryotherapy device for use by frontline health care providers at locations where screening and timely treatment can be given, accelerating access to cervical cancer prevention services and minimizing loss to follow-up of women with precancerous lesions who need treatment. Trial registration Clinical Trial Registry - India CTRI/2019/01/017289 ClinicalTrials.Gov number NCT04154644. Registered on November 6, 2019.

scholarly journals Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer

2013 ◽  
Vol 22 (11) ◽  
pp. 1239-1244 ◽  
Author(s):  
Seoyoung C. Kim ◽  
Victoria G. Gillet ◽  
Sarah Feldman ◽  
Huichuan Lii ◽  
Sengwee Toh ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cervical Dysplasia ◽  
High Grade

Cervical Cancer Screening

2018 ◽  
Author(s):  
Huma Farid
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Pap Smear ◽  
Cervical Dysplasia ◽  
The United States ◽  
Pap Smears ◽  
Low Grade ◽  
High Grade

Since the Papanicolaou (Pap) smear became implemented as a screening tool for cervical cancer, the mortality from cervical cancer has sharply declined in the United States. The discovery of the human papillomavirus (HPV) as the causative agent in the progression from dysplasia of the cervix to cervical cancer has changed the types of screening offered to women and the management of abnormal Pap smears. The management of abnormal Pap smears has changed depending on the age of the woman, with women under the age of 24 years being managed more conservatively given the low rates of cervical cancer in this age group and the high rates of regression of HPV and cytologic abnormalities. Colposcopy remains the first line in evaluation of an abnormal Pap smear, with excisional treatment reserved for high-grade dysplasias with a high risk of progression to cervical cancer. Treatment for cervical dysplasia is highly effective, but even after treatment, there is an increased risk of recurrence or progression to cervical cancer for up to 20 years, and these women should be followed closely. This review contains 18 figures, 3 tables and 53 references Key words: cervical cancer screening, high-grade cervical dysplasia, human papillomavirus, low-grade cervical dysplasia, management of abnormal Pap smears, Pap smear, recurrence of cervical dysplasia, treatment of dysplasia

scholarly journals Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study

2016 ◽  
Vol 68 (9) ◽  
pp. 2106-2113 ◽  
Author(s):  
Seoyoung C. Kim ◽  
Sebastian Schneeweiss ◽  
Jun Liu ◽  
Elizabeth W. Karlson ◽  
Jeffrey N. Katz ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cervical Cancer ◽  
Cohort Study ◽  
Cervical Dysplasia ◽  
High Grade ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Disease Modifying

scholarly journals Tumor microbial diversity and compositional differences among women in Botswana with high-grade cervical dysplasia and cervical cancer

2020 ◽  
Vol 30 (8) ◽  
pp. 1151-1156
Author(s):  
Travis T Sims ◽  
Greyson W G Biegert ◽  
Doreen Ramogola-Masire ◽  
Kebatshabile Ngoni ◽  
Travis Solley ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Discriminant Analysis ◽  
Linear Discriminant Analysis ◽  
Effect Size ◽  
Beta Diversity ◽  
Cervical Dysplasia ◽  
Alpha Diversity ◽  
Sub Saharan Africa ◽  
High Grade ◽  
Linear Discriminant

IntroductionWe characterized the cervical 16S rDNA microbiome of patients in Botswana with high-grade cervical dysplasia and locally advanced cervical cancer.MethodsThis prospective study included 31 patients: 21 with dysplasia and 10 with cancer. The Shannon diversity index was used to evaluate alpha (intra-sample) diversity, while the UniFrac (weighted and unweighted) and Bray–Curtis distances were employed to evaluate beta (inter-sample) diversity. The relative abundance of microbial taxa was compared among samples using linear discriminant analysis effect size.ResultsAlpha diversity was significantly higher in patients with cervical cancer than in patients with cervical dysplasia (P<0.05). Beta diversity also differed significantly (weighted UniFrac Bray–Curtis, P<0.01). Neither alpha diversity (P=0.8) nor beta diversity (P=0.19) varied by HIV status. The results of linear discriminant analysis effect size demonstrated that multiple taxa differed significantly between patients with cervical dysplasia vs cancer. Lachnospira bacteria (in the Clostridia class) were particularly enriched among cervical dysplasia patients, while Proteobacteria (members of the Firmicutes phyla and the Comamonadaceae family) were enriched in patients with cervical cancer.DiscussionThe results of our study suggest that differences exist in the diversity and composition of the cervical microbiota between patients with cervical dysplasia and patients with cervical cancer in Botswana. Additional studies are warranted to validate these findings and elucidate their clinical significance among women living in sub-Saharan Africa, as well as other regions of the world.

Sign in / Sign up

Export Citation Format

Share Document